In Race to Treat Muscle-Wasting Disease, Sarepta Seeks Purchases July 14, 2015 — 11:00 AM CEST Sarepta Therapeutics Inc. is looking to buy another drug in an escalating battle with bigger rival BioMarin Pharmaceutical Inc. to treat Duchenne muscular dystrophy, the rare and deadly muscle-wasting disease. The two companies are in a race to bring the products to market, and buying a drug could let Sarepta eventually combine therapies into a more effective cocktail. BioMarin submitted its drug to the U.S. Food and Drug Administration in April, beating Cambridge, Massachusetts-based Sarepta by a matter of weeks. With the two drugmakers racing neck-and-neck at the FDA, Sarepta’s interim Chief Executive Officer Edward Kaye said the company’s next move will be to buy another therapy, potentially to use in a cocktail of treatments for the muscle-wasting disease, which occurs in about one of 3,500 boys born worldwide, according to the U.S. National Institutes of Health. “We are going to own DMD,” Kaye said in an interview. The company, he said, wants “a menu of options” to offer patients, and is looking for an acquisition within a year. source http://www.bloomberg.com/news/articles/2015-07 -14/in-race-to-treat-musc le-wasting-disease-sarept a-seeks-purchases
bizzare j ai trouvé ce post sjr boursorama mais il a été supprimé
